Text Size

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.


  • 2025
  • Expert Rev Pharmacoecon Outcomes Res
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Oftalvist Clinic, Barcelona, Spain. Department of Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain; Instituto Ramón Castroviejo, Universidad Complutense, Madrid, Spain. Department of Ophthalmology, Hospital Miguel Servet, Zaragoza, Spain; Department of Ophthalmology, Hospital Clínico de Santiago, Santiago de Compostela, Spain; Instituto Oftalmológico Gómez-Ulla, Santiago de Compostela, Spain; Institut Clínic d'Oftalmologia, Hospital Clínic de Barcelona, Barcelona, Spain; Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain; Santen Pharmaceutical, Madrid, Spain.

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022